The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Share News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: -0.25 (-3.28%)
Spread: 0.25 (3.448%)
Open: 7.625
High: 7.625
Low: 7.375
Prev. Close: 7.625
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Andrada raises GBP7.7 million; Ixico signs contract

Tue, 18th Jul 2023 16:55

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Ixico PLC - London-based precision analytics company delivering insights in neuroscience - Signs a contract with a new, unnamed client. Under the agreement, Ixico will provide its imaging services in a clinical trial of a novel therapeutic to treat progressive supranuclear palsy, a rare neurodegenerative disease. Says the contract value is about USD1.7 million, over a four-year term. Chief Executive Giulio Cerroni says: "Rare diseases are a global health priority with about 95% of all rare diseases not yet having treatments. This new contract exemplifies the traction we are building beyond our strong market position in HD into other rare neuro disorders to expand our market opportunities and acquire new clients in the dynamic field of rare neurological diseases."

----------

DX Group PLC - Slough, England-based provider of delivery solutions, including parcel freight, secure courier and logistics services - Says that it has traded in line with management's expectations during the second half of the company's financial year ended July 1. Revenue for the financial year is expected to be 10% ahead of the prior year at GBP470 million, up from GBP428 million. Says net cash at July 1 was up by 39% to GBP37.6 million from GBP27.0 million, which it says is slightly ahead of management's target. Both DX Freight and DX Express contributed increased revenue and achieved margin gains, it adds. Looking ahead, DX says it remains "encouraged about growth prospects", despite the current economic headwinds. Plans to publish its full-year results in early October.

----------

Judges Scientific PLC - London-based acquirer of scientific-instrument companies - Says that organic order intake in the first half of 2023 was up 14% year-on-year. Adds that it was up in all major regions, signalling improving prospects across markets, with the most notable being China/Hong Kong. North America was up 6.6%, the UK up 9.0%, the rest of Europe up 7.5% and the rest of the world up 3.5%. Says organic revenue in the first half was up 17% compared with the first half of 2022, illustrating some progress with supply chain issues. Noted that two "small acquisitions" were completed during the first half, Henniker Scientific Ltd and Bossa Nova Vision LLC. "The strong order book, and the general resilience of Judges' business give the board confidence that the current market expectations for the full year will be met," Judges says, looking ahead. Plans on announcing its interim results on September 20.

----------

Gulf Marine Services PLC - United Arab Emirates-based lift boat company - Says that financing charges will decline as paid in kind interest stops accruing as of the second quarter, as a result of net leverage dropping below 4:1. This means that moving forward, the cost of funds will decrease by 340 basis points. Executive Chair Mansour Al Alami says: "We are delighted to make this announcement that confirms that our continuous commitment to deleverage is successful in moving value from lenders to shareholders. Reaching this milestone will enable us to better face all other challenges while continuing our deleveraging journey."

----------

Bloomsbury Publishing PLC - London-based publisher - Says trading has been in line with expectations following a good performance in the first four months of its financial year. Says it has maintained year-on-year sales growth of 9% in the four months ended June 30. "The board remains confident in Bloomsbury's ability to continue to deliver long-term success, with significant financial resources available to invest in organic growth and further company acquisitions. Global diversification across channels and markets continues to serve us well and further underpins our positive outlook," it adds. The results for the six months ending August 31 will be announced on October 26.

----------

Marlowe PLC - London-based software & service provider for safety and regulatory compliance - Says a resolution was passed by shareholders to cancel the balance standing to the credit of the company's share premium account. In doing so, the company will increase its distributable reserves by GBP384.9 million. Says it remains focussed on the continued execution of its growth strategy, and the capital reduction now removes a potential restriction on the company's ability to either make dividend payments and other distributions or to purchase its own shares in the future.

----------

ACG Acquisition Co Ltd - Special purpose acquisition company looking to benefit from favourable price conditions for new economy metals and other mining materials - In June, ACG said it will be renamed to ACG Electric Metals Ltd as it invests in two Brazilian mines to supply metals to electric vehicle makers. ACG Acquisition said it purchased the Atlantic nickel sulphide mine and the Mineracao Vale Verde copper mine in Brazil for USD1.0 billion from funds advised by Appian Capital Advisory LLP, as it looks to become a "new leader in green critical metals". On Tuesday, it says it has postpone its equity offer amid asset purchase talks. "ACG is discussing potential improvements to the transaction structure," the company says. It noted that it has paused the book building process for the placing for a "short period of time" and will reschedule the acquisition extraordinary general meeting to a later date in July. The scheduled date for the completion of the acquisition and settlement of the placing remains August 4.

----------

BioPharma Credit PLC - specialist life sciences debt investment trust - Notes filing by LumiraDx Ltd which discloses an amendment to the loan agreement entered into with BioPharma Credit, BPCR LP, and BioPharma Credit Investments V (Master) LP. On Monday, LumiraDx said it had amended its loan agreement, by extending the time it has to comply with certain minimum net sales and minimum liquidity covenants in the agreement until July 20.

----------

Litigation Capital Management Ltd - asset manager specialising in dispute financing solutions - Says it has reviewed its accounting policies and will now transition to fair value accounting. Says that this will put LCM in line with industry peers in both accounting policy and fair value framework. In doing so, it expects to announce its financial 2023 results under both the existing accounting policies as well as the newly adopted fair value accounting. "This will provide our investors with better transparency on the impact of the transition," it says. Adds that it has decided to pay a dividend of 2.25p to shareholders for financial 2023. CEO Patrick Moloney comments: "We are pleased with the performance of the business over the past 12 months, particularly as we begin to see the benefits of moving to a fund management business model. Our strong financial performance is the best in LCM's history and reflected in the board's decision to pay a dividend."

----------

Investment Co PLC - Newton Abbot, London-based investment trust - Tenders 4.0 million shares, constituting around 83% of the existing share capital. In addition, it receives total commitments of approximately GBP3.6 million pursuant to its placing, offer for subscription and intermediaries offer. The issue price will be calculated on or around 1800 BST Tuesday.

----------

Andrada Mining Ltd - Technology metals mining company with a portfolio of mining and exploration assets in Namibia - Raises GBP7.7 million through the issue of 77 unsecured, convertible loan notes of GBP100,000 each to new and existing investors. Also confirm that it has also completed the construction phase of the bulk sampling plant and tantalum circuit. CEO Anthony Viljoen says: "The proceeds are to be used for ongoing capital expansion programmes related to the lithium and tantalum development. In addition, the funds will be used for working capital purposes as Andrada progresses its exploration programme, and commences a lithium feasibility study, to further consolidate its competitive lithium advantage within the Erongo region of Namibia."

----------

Topps Tiles PLC - Leicestershire-based retailer - Notes shareholder disapproval at annual general meeting on January 18. At the time resolution 15 - short notice for meetings other than AGMs - did not pass, seven others passed with less than 80% of votes cast in favour. Says that since then the board has engaged with the relevant shareholder to understand and discuss their views with respect to these resolutions. "Whilst the board fully respects and acknowledges that a shareholder may choose to vote against specific resolutions, the board considers all the resolutions proposed to be in the best interests of all shareholders," Topps adds.

----------

CPPGroup PLC - Leeds, England-based technology-driven assistance company - Expects revenue from continuing operations in the first half of 2023 to be about 22% ahead of the prior year, and, on a constant currency basis, to be ahead of the prior year by 26%. Earnings before interest, tax, depreciation and amortisation from continuing operations is expected to be broadly in line with the prior year at about GBP2.9 million, unchanged from GBP2.9 million in the first half of 2022. CEO Simon Pyper says: "From a trading perspective the group's performance in the first half was encouraging. Additionally, growth, renewals, and new client wins in Blink provide strong evidence that our strategy and approach is appropriate, and more importantly, starting to deliver positive outcomes, though at a somewhat more measured pace than originally expected." Plans to publish its interim results for the first half of the year on September 19.

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Oct 2021 09:33

Ixico FY revenues projected to beat expectations

(Sharecast News) - AI data analytics company Ixico said on Monday that full-year revenues were projected to have beat expectations despite falling shy of prior year comparatives.

Read more
22 Sep 2021 11:19

Ixico secures new contract valued at more than $750,000

(Sharecast News) - AI data analytics firm Ixico has secured a new contract valued at more than $750,000 over two years for advanced neuroimaging solutions.

Read more
8 Sep 2021 12:47

Ixico awarded phase 1 clinical trial contract

(Sharecast News) - Neuroscience artificial intelligence (AI) company Ixico has been awarded a contract by a new biopharmaceutical client to support its phase 1 multiple system atrophy clinical trial, it announced on Wednesday.

Read more
6 Aug 2021 14:53

Ixico confident as full-year revenue, earnings decline

(Sharecast News) - Data analytics company Ixico updated the market on its trading on Friday, confirming that despite a "challenging" business environment, it expected to deliver £8.7m in revenues for the 2021 financial year.

Read more
26 Apr 2021 09:06

Ixico H1 revenues grow despite Covid-19 impacts on clinical development sector

(Sharecast News) - Clinical research firm Ixico said on Monday that revenues were expected to have improved in the six months ended 31 March, despite the impacts of the Covid-19 pandemic on the clinical development sector.

Read more
15 Mar 2021 10:13

Ixico strikes collaboration deal with Microsoft

(Sharecast News) - Data analytics company Ixico said on Monday that it had struck a collaboration agreement with tech giant Microsoft to develop its artificial intelligence analytics platform for the global pharmaceutical industry.

Read more
10 Mar 2021 14:30

Ixico selected for Alzheimer's clinical trial

(Sharecast News) - Neuroscience artificial intelligence (AI) analytics company Ixico has been selected by a current mid-sized biopharmaceutical client to support a phase 2 Alzheimer's disease clinical trial, it announced on Wednesday.

Read more
24 Dec 2020 12:20

Ixico awarded ?3.4m contract by existing client

(Sharecast News) - Artificial intelligence (AI) data analytics company Ixico has been awarded a £3.4m contract to run over 4.5 years by an existing client, it announced on Thursday, for a spinocerebellar ataxia type-3 (SCA3) trial.

Read more
8 Dec 2020 09:26

Ixico to provide neuroimaging solutions to unnamed global pharmaceutical group

(Sharecast News) - Data analytics firm Ixico has secured a contract for neuroimaging solutions with a "large global pharmaceutical company".

Read more
27 Nov 2020 12:09

Ixico executes contract for Huntington's disease clinical trial

(Sharecast News) - Neuroscience data analytics company Ixico has executed a contract to provide neuroimaging services that would support a phase 1b and 2 clinical trial for Huntington's disease, it announced on Friday.

Read more
3 Nov 2020 10:43

Ixico wins new contracts in Alzheimer's clinical trials

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Alzheimer's disease (AD) clinical trials, it announced on Tuesday.

Read more
22 Oct 2020 15:00

Ixico secures two Huntington's disease clinical trial contracts

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Huntington's disease clinical trials.

Read more
19 Oct 2020 09:38

Ixico FY revenues grow by more than a quarter

(Sharecast News) - AI data analytics company Ixico said on Monday that full-year revenues were up year-on-year as its data analytics service strategy continued to drive growth.

Read more
16 Oct 2020 16:23

Ixico enters deal with NUY Langone Health for drug trial

(Sharecast News) - Data analytics company Ixico has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus, approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomyomatosis, is also able to slow the progression of disease in people with multiple system atrophy (MSA).

Read more
24 Sep 2020 16:30

Ixico joins Friedreich's Ataxia research consortium

(Sharecast News) - Data analytics company Ixico has entered into a five-year collaboration with the Friedreich's Ataxia Research Alliance (FARA), it announced on Thursday, which it described as a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.